<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="87165">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01666951</url>
  </required_header>
  <id_info>
    <org_study_id>LCP-Tacro 2019</org_study_id>
    <nct_id>NCT01666951</nct_id>
  </id_info>
  <brief_title>A Phase 2 Double-Blind, Double-dummy, Multicenter, Prospective, Randomized Study of the Pharmacokinetics of LCP-Tacro Tablets, Once-Daily, Compared to Prograf Capsules, Twice-daily, for the Prevention of Acute Allograft Rejection in De Novo Adult Kidney Transplant Recipients</brief_title>
  <official_title>A Phase 2 Double-Blind, Double-dummy, Multicenter, Prospective, Randomized Study of the Pharmacokinetics of LCP-Tacro Tablets, Once-Daily, Compared to Prograf Capsules, Twice-daily, for the Prevention of Acute Allograft Rejection in De Novo Adult Kidney Transplant Recipients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Veloxis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Veloxis Pharmaceuticals</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the pharmacokinetics of LCP-Tacro tablets
      administered once-daily compared to Prograf capsules administered twice-daily after kidney
      transplantation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a 2-arm , parallel group, prospective, double-blind, double-dummy,
      multicenter,clinical trial to evaluate the pharmacokinetics of LCP-Tacro tablets once daily
      in comparison to Prograf capsules twice-daily after kidney transplantation.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>24 hour Pharmacokinetic profile of LCP-Tacro vs Prograf on Days 1, 14 and 28 in adult de novo kidney recipients</measure>
    <time_frame>28 days</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of 24-hour pharmacokinetic profiles, safety, pharmacodynamics (ambulatory blood pressure monitoring) and efficacy (death, graft failure and centrally read biopsy-proven acute rejection) of LCP-Tacro vs Prograf in 28 days.</measure>
    <time_frame>28 days</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Renal Failure</condition>
  <arm_group>
    <arm_group_label>LCP-Tacro</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LCP-Tacro Tablets, once daily (Veloxis Pharmaceuticals A/S, Horsholm, DK)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prograf</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Prograf Capsules, twice daily (Astellas Pharma US, Deerfield, IL)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LCP-Tacro tablets</intervention_name>
    <description>Tacrolimus</description>
    <arm_group_label>LCP-Tacro</arm_group_label>
    <other_name>Prograf</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prograf</intervention_name>
    <description>Tacrolimus</description>
    <arm_group_label>Prograf</arm_group_label>
    <other_name>Prograf Capsules twice daily</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects must be able to give written consent.

          -  Male and female subjects between the ages of 18 and 70 years, inclusive.

          -  Subjects must be receiving primary or secondary renal allograft from a deceased donor
             or non-HLA identical living donor.

          -  Women of childbearing potential (WOCBP) must have a negative pregnancy test (serum or
             urine pregnancy test with a sensitivity of a least 25 mIU/ml) within 1 week prior to
             randomization or in accordance with local regulations, whichever is of shorter
             duration.  All subjects must agree to follow the contraceptive guidelines as detained
             in section 8.2.4.

          -  Subjects must have negative cross-match test and be ABO-compatible.

          -  Subjects must be able to swallow tablets and capsules

        Exclusion Criteria:

          -  Subjects who are recipients of any previous non-renal concurrent transplant (solid
             organ or bone marrow)

          -  Subjects who have panel reactive antibody &gt; 50%

          -  Subjects with any condition that may affect study drug absorption (eg, gastrectomy or
             clinically significant diabetic gastroenteropathy, inflammatory bowel disease, or
             gastric bypass)

          -  Subjects with body mass index (BMI) , 18 kg/m2 or &gt; 45 kg/m2, calculated using the
             formula of BMI = mass/(height2)

          -  Subjects with history of alcohol abuse with less than 6 months of sobriety

          -  Subjects with history  of recreational drug abuse with less than 6 months of
             documented abstinence

          -  Subjects with screening 12-lead ECG demonstrating clinically significant
             abnormalities (including QTc prolongation)

          -  Subjects who are WOCBP and are either pregnant, lactating, planning to become
             pregnant or with a positive serum or urine pregnancy test

          -  Subjects (male  or female) with reproductive potential who are unwilling/unable to
             use a double-barrier method of contraception and follow the contraception guidelines
             in 8.2.4

          -  Subjects with an oral temperature (prior to study drug dosing) of 38C (100.4F) or
             higher

          -  Subjects with clinically significant active infections (eg, those requiring
             hospitalization, or as judged by the Investigator)

          -  Subjects with known hereditary immunodeficiency

          -  Subjects with malignancies or with a history of malignancies (within the last 5
             years) with the exception of local, noninvasive, fully excised cutaneous basal cell
             carcinoma, cutaneous squamous cell carcinoma, or cervical carinoma in situ

          -  Subjects who expect to receive within 2 months after randomization, or have received
             within 3 months prior to screening, any of the following: sirolimus, everolimus,
             belatacept, or cyclophosphamide

          -  Subjects with any psychiatric or medical condition (cardiac, pulmonary, central
             nervous system, gastrointestinal, endocrine/metabolic, etc) that, in the
             Investigator's opinion, may put the subject at significant risk, may confound the
             study results, or may interfere significantly with the subject's participation in the
             study

          -  Subjects with clinically symptomatic congestive heart failure or documented rejection
             fraction of less than 45%

          -  Subjects with significant chronic obstructive pulmonary disease, pulmonary
             restrictive disease or significant pulmonary hypertension

          -  Subjects currently enrolled in another investigational drug or device study, who are
             less than 30 days since discontinuing another investigational drug or device study,
             or who are currently receiving other investigational treatment

          -  Subjects with laboratory variables that are abnormal (outside laboratory reference
             range) and clinically significant as judged by the Investigator

          -  Subjects with positive results of any of the following serological tests: human
             immunodeficiency virus (HIV)-1 antibody, hepatitis B virus (HBV) surface antigen
             (HBsAg), anti-hepatitis B core antibody (HBcAb), and anti-hepatitis C virus (HCV)
             antibody (HCV Ab). Negative results for these serological tests much be documented
             within 12 months prior to randomization

          -  Subjects who have had primary focal segmental glomerulosclerosis

          -  Donor parameters must not include any of the following known conditions:

        Positive serological test result for HIV-1, HBV or HCV History of malignant disease
        (current or historical) Cold ischemia time &gt; 30 hours Non-heart-beating donor
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Clinical Investigative Site 000015</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Investigative Site 000012</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Investigative Site 00004</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Investigative Site 000002</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Investigative Site 000005</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536-0293</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Investigative Site 000009</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Investigative Site 000010</name>
      <address>
        <city>Livingston</city>
        <state>New Jersey</state>
        <zip>07039</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Investigative Site 000011</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Investigative Site 00006</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Investigative Site 00008</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Investigative Site 00003</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Investigative Site 000013</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Investigative Site 00001</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <lastchanged_date>September 9, 2013</lastchanged_date>
  <firstreceived_date>August 14, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
